Robust and accurate biomarker tests to solve clinical questions
Elecsys® β-Amyloid(1-42) CSF II (AB42 2) is an in vitro diagnostic immunoassay intended for the quantitative determination of the β-Amyloid(1-42) protein concentration in human cerebrospinal fluid (CSF).1
Elecsys® AB42 2 assay is part of the Elecsys® AD portfolio, along with Elecsys® Phospho-Tau (181P) CSF (pTau) and Elecsys® Total-Tau CSF (tTau) immunoassays.1
Elecsys® AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.2,3
Elecsys® AD CSF assays enable timely intervention by identifying patients with MCI at risk of progression to AD.1,3
Robust, clinically validated results to help ensure patients get the care they deserve
References